Wave Life Sciences Ltd.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
WVE$3.48+3.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share amounts)
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $602,068 | $302,078 |
| Accounts receivable | 1,276 | 1,422 |
| Prepaid expenses | 8,395 | 9,544 |
| Other current assets | 3,075 | 7,350 |
| Total current assets | 614,814 | 320,394 |
| Long-term assets: | ||
| Property and equipment, net of accumulated depreciation of $49,522 and $46,329 as of December 31, 2025 and 2024, respectively | 7,405 | 10,128 |
| Operating lease right-of-use assets | 12,458 | 17,870 |
| Restricted cash | 3,806 | 3,760 |
| Other assets | 16 | 55 |
| Total long-term assets | 23,685 | 31,813 |
| Total assets | $638,499 | $352,207 |
| Liabilities, Series A preferred shares and shareholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $15,700 | $16,262 |
| Accrued expenses and other current liabilities | 26,564 | 21,081 |
| Current portion of deferred revenue | 44,440 | 65,972 |
| Current portion of operating lease liability | 8,361 | 7,638 |
| Total current liabilities | 95,065 | 110,953 |
| Long-term liabilities: | ||
| Deferred revenue, net of current portion | 7,798 | 6,099 |
| Operating lease liability, net of current portion | 9,405 | 17,766 |
| Total long-term liabilities | 17,203 | 23,865 |
| Total liabilities | $112,268 | $134,818 |
| Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at December 31, 2025 and 2024 | $7,874 | $7,874 |
| Shareholders’ equity: | ||
| Ordinary shares, no par value; 187,660,263 and 153,037,286 shares issued and outstanding at December 31, 2025 and 2024, respectively | $1,616,478 | $1,175,181 |
| Additional paid-in capital | 228,365 | 156,454 |
| Accumulated other comprehensive loss | (250) | (262) |
| Accumulated deficit | (1,326,236) | (1,121,858) |
| Total shareholders’ equity | 518,357 | 209,515 |
| Total liabilities, Series A preferred shares and shareholders’ equity | $638,499 | $352,207 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.